← Research

Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial

Bradley ER, Kelley DP, Szigeti B, et al. — UCSF / Columbia University

Published in JAMA Psychiatry

Research letter from UCSF's open-label pilot in 12 adults with mild to moderate Parkinson's and mood symptoms (10 mg then 25 mg psilocybin, about two weeks apart). In plasma from 9 participants, a composite inflammatory index was significantly lower 1 day after each dose and 30 days after the second; the mitochondrial stress marker GDF-15 fell 1 day after each dose but not at 30 days. No control group and no blinding, so the changes can't be attributed to psilocybin; the authors call for controlled trials with longer follow-up.

Read the Full Paper at JAMA Psychiatry